Creating Opportunity in the Life Sciences Industry with Modeling and Simulation
The Healthcare environment and the broader Life Sciences Industry ecosystem are rapidly changing. On account of rising costs, new technologies, time-to-market demands, and strict regulations are compelling a comprehensive reassessment of the industry across all fronts. This includes business operations, research and development processes, and value-based pricing options.
Life Sciences organizations are adopting novel methods like modeling and simulation throughout their value chain. This adaption is to conquer challenges, enhance collaborative decision making, save time and money, improve patient outcomes, and stay competitive.
By using modeling and simulation applications within an integrated, digitally managed and collaborative computing environment such as Dassault Systèmes’ 3DEXPERIENCE® platform, organizations are able to create lifelike simulation models for exploration, discovery, development, testing, and commercialization.
Benefits of Using a Collaborative, Data-Driven, Model-Based Platform:
- Reduce the number of labor-intensive tasks and also introduce automation
- Foster collaboration and knowledge sharing throughout the value chain
- Expand networks of collaboration/cooperation beyond the enterprise
- Accelerate innovation and regulatory approval processes
- Minimize cost while increasing value to patients
Summing up, the use of modeling and simulation on the 3DEXPERIENCE platform enables the Life Sciences Industry to optimize their long-term enterprise sustainability. In addition, the ability to meet their objectives in terms of cost, innovation, and services.
Complete the form to read our eBook.
SIMULIA Introduces the Living Heart Project | Life Sciences Industry
Dassault Systèmes has unveiled the world’s first 3D realistic simulation model of a whole human heart. Developed with a multidisciplinary team of heart experts to help combat cardiovascular disease. The “Living Heart Project” will launch the next frontier in diagnosing, treating, and preventing heart conditions through personalized, 3D virtual models.
Modeling and simulation can help to inform clinical trial designs, support evidence of effectiveness, identify the most relevant patients to study, and assess product safety. In some cases, in silico clinical trials have already been shown to produce similar results as human clinical trials.
– Tina Morrison, Ph.D.,
Deputy Director in the Division of Applied Mechanics, Office of Science and Engineering Labs, Center for Devices and Radiological Health, FDA
Extended Collaboration for Cardiovascular Device and New Treatments
Read about the groundbreaking approach that aims to foster industry innovation as well as expedite patient access to safe and effective treatments for heart disease.
Discover how Abaqus FEA by Dassault Systèmes SIMULIA enabled GN ReSound to simulate and fortify their devices against impact, ensuring product durability for patient use.